01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported second-quarter 2024 net sales of $807.2 milliona, down 5% from $846.2 million a year earlier, with organic net sales down 4%.
The decline reflected lower volumes, largely in the Health & Science Technologies segment, partly offset by price capture and strong price/cost and productivity across segments. Net income attributable to IDEX rose 2% to $141.3 million, and diluted EPS increased to $1.86b from $1.82. Adjusted net income attributable to IDEX fell 6% to $156.1 million, and Adjusted EBITDA declined 7% to $224.2 million, with the Adjusted EBITDA margin at 27.8% versus 28.4%.
Gross margin improved to 45.4% from 44.7%, and operating income fell 9% to $182.7 millionc. For the first half of 2024, net sales were $1,607.7 million, down 5%, and net income attributable to IDEX was $262.7 million. Cash flow from operations was $290.2 million, and free cash flow was $254.3 million.
Cash and cash equivalents totaled $700.7 milliond at June 30, 2024, and the Revolving Facility had $719.2 million of net availability. The company paid $100.7 million in dividends during the six months and made no share repurchases, leaving $539.7 million of authorization remaining. The company was in compliance with its financial covenants at June 30, 2024.
Looking ahead, IDEX entered into a definitive agreement on July 23, 2024 to acquire Mott Corporation for $1.0 billion in cash, expected to close by the end of the third quarter of 2024 subject to regulatory approvals. The acquisition is expected to be funded with cash on hand, borrowings under the Revolving Credit Facility and potential debt issuance. The company also acquired Subterra AI, Inc. for $7.5 million on July 25, 2024.
02—Key points
Key Highlights
- Net sales were $807.2 million for the quarter, down 5% from $846.2 million, with organic net sales down 4% due to lower volumes, mainly in Health & Science Technologies.
- Net income attributable to IDEX increased 2% to $141.3 million, and diluted EPS rose to $1.86 from $1.82, while Adjusted diluted EPS fell 6% to $2.06.
- Adjusted EBITDA declined 7% to $224.2 million, and the Adjusted EBITDA margin was 27.8% compared with 28.4% in the prior-year quarter.
- Gross margin improved to 45.4% from 44.7%, supported by strong price/cost and operational productivity.
- Health & Science Technologies net sales fell 11% to $303.0 million, while Fluid & Metering Technologies net sales declined 2% and Fire & Safety/Diversified Products net sales were flat at $185.3 million.
- The company agreed to acquire Mott Corporation for $1.0 billion in cash, expected to close by the end of the third quarter of 2024.
- Cash and cash equivalents were $700.7 million at June 30, 2024, and the company repaid $25.0 million of its Term Facility during the second quarter.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Idex kept $0.18.
- Revenue$807.2M100.0%
- Cost of revenue−$440.4M54.6%
- Gross profit$366.8M45.4%
- Operating costs−$184.1M22.8%
- Operating income$182.7M22.6%
- Interest, other & tax−$41.4M5.1%
- Net income$141.3M17.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $807.20M$846.20M | −4.6% |
| Cost of Revenue | $440.40M$468.20M | −5.9% |
| Gross Profit | $366.80M$378.00M | −3.0% |
| SG&A Expenses | $182.80M$174.30M | +4.9% |
| Operating Income | $182.70M$200.10M | −8.7% |
| Interest Expense | $8.10M$13.30M | −39.1% |
| Net Income | $141.30M$138.50M | +2.0% |
| EPS (Basic) | $1.86$1.83 | +1.6% |
| EPS (Diluted) | $1.86$1.82 | +2.2% |
| Shares Outstanding (Basic) | 75.70M75.60M | +0.1% |
| Shares Outstanding (Diluted) | 75.90M75.90M | 0.0% |
05—Questions
Frequently Asked Questions
Why did IDEX's sales decline in the second quarter of 2024?
Net sales decreased 5% to $807.2 million, and organic net sales decreased 4%. The filing attributes this to lower volumes, largely from market conditions in the Health & Science Technologies businesses, partially offset by price capture across all segments.
How did profitability change despite lower sales?
Diluted EPS attributable to IDEX rose to $1.86 from $1.82, and net income attributable to IDEX increased 2% to $141.3 million. The filing cites a $7.7 million credit loss reserve recorded in the prior-year period that did not recur, along with a lower effective tax rate of 21.2% versus 22.4%. Adjusted net income, however, declined 6%.
What is the Mott Corporation acquisition and how will it be funded?
On July 23, 2024, IDEX agreed to acquire Mott Corporation, a microfiltration business, for $1.0 billion in cash, subject to customary adjustments. The company expects to close by the end of the third quarter of 2024, subject to regulatory approvals, and plans to fund it with cash on hand, borrowings under its Revolving Credit Facility and potential debt issuance. Mott will operate in the Health & Science Technologies segment.
What is the company's liquidity and balance sheet position?
At June 30, 2024, IDEX had cash and cash equivalents of $700.7 million, of which $558.8 million was held outside the United States. Revolving Facility availability was $719.2 million, and total borrowings were $1,304.9 million. The company stated it was in compliance with its financial covenants, with an interest coverage ratio of 18.73 to 1 and a leverage ratio of 1.50 to 1.
06—Continue